This clinical trial, sponsored by M.D. Anderson Cancer Center, investigates the efficacy of a novel conditioning regimen combining venetoclax with busulfan, cladribine, and fludarabine prior to allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The trial's design aims to enhance progression-free survival and overall survival rates, potentially positioning venetoclax as a critical component in pre-transplant conditioning regimens. Given the significant unmet need in AML and MDS treatment, successful outcomes could lead to a competitive advantage in the hematologic oncology market, particularly in the context of stem cell transplantation. The collaboration with the National Cancer Institute (NCI) may also enhance credibility and facilitate broader acceptance within the oncology community.